PURPOSE: Patients with non-Hodgkin lymphoma including chronic lymphocytic leukemia (NHL/CLL) are at higher risk of severe SARS-CoV-2 infection. We investigated vaccine-induced antibody responses in patients with NHL/CLL against the original SARS-CoV-2 strain and variants of concern including B.1.167.2 (Delta) and B.1.1.529 (Omicron). MATERIALS AND METHODS: Blood from 121 patients with NHL/CLL receiving two doses of vaccine were collected longitudinally. Antibody binding against the full-length spike protein, the receptor-binding, and N-terminal domains of the original strain and of variants was measured using a multiplex assay. Live-virus neutralization against Delta, Omicron, and the early WA1/2020 strains was measured using a focus reduction neutralization test. B cells were measured by flow cytometry. Correlation between vaccine response and clinical factors was determined. RESULTS: Mean anti-SARS-CoV-2 spike immunoglobulin G-binding titers were 85-fold lower in patients with NHL/CLL compared with healthy controls, with seroconversion occurring in only 67% of patients. Neutralization titers were also lower and correlated with binding titers (P < .0001). Treatment with anti-CD20-directed therapies within 1 year resulted in 136-fold lower binding titers. Peripheral blood B-cell count also correlated with vaccine response. At 3 months from last anti-CD20-directed therapy, B-cell count ≥ 4.31/μL blood around the time of vaccination predicted response (OR 7.46, P = .04). Antibody responses also correlated with age. Importantly, neutralization titers against Delta and Omicron were reduced six- and 42-fold, respectively, with 67% of patients seropositive for WA1/2020 exhibiting seronegativity for Omicron. CONCLUSION: Antibody binding and live-virus neutralization against SARS-CoV-2 and its variants of concern including Delta and Omicron were substantially lower in patients with NHL/CLL compared with healthy vaccinees. Anti-CD20-directed therapy < 1 year before vaccination and number of circulating B cells strongly predict vaccine response.
PURPOSE: Patients with non-Hodgkin lymphoma including chronic lymphocytic leukemia (NHL/CLL) are at higher risk of severe SARS-CoV-2 infection. We investigated vaccine-induced antibody responses in patients with NHL/CLL against the original SARS-CoV-2 strain and variants of concern including B.1.167.2 (Delta) and B.1.1.529 (Omicron). MATERIALS AND METHODS: Blood from 121 patients with NHL/CLL receiving two doses of vaccine were collected longitudinally. Antibody binding against the full-length spike protein, the receptor-binding, and N-terminal domains of the original strain and of variants was measured using a multiplex assay. Live-virus neutralization against Delta, Omicron, and the early WA1/2020 strains was measured using a focus reduction neutralization test. B cells were measured by flow cytometry. Correlation between vaccine response and clinical factors was determined. RESULTS: Mean anti-SARS-CoV-2 spike immunoglobulin G-binding titers were 85-fold lower in patients with NHL/CLL compared with healthy controls, with seroconversion occurring in only 67% of patients. Neutralization titers were also lower and correlated with binding titers (P < .0001). Treatment with anti-CD20-directed therapies within 1 year resulted in 136-fold lower binding titers. Peripheral blood B-cell count also correlated with vaccine response. At 3 months from last anti-CD20-directed therapy, B-cell count ≥ 4.31/μL blood around the time of vaccination predicted response (OR 7.46, P = .04). Antibody responses also correlated with age. Importantly, neutralization titers against Delta and Omicron were reduced six- and 42-fold, respectively, with 67% of patients seropositive for WA1/2020 exhibiting seronegativity for Omicron. CONCLUSION: Antibody binding and live-virus neutralization against SARS-CoV-2 and its variants of concern including Delta and Omicron were substantially lower in patients with NHL/CLL compared with healthy vaccinees. Anti-CD20-directed therapy < 1 year before vaccination and number of circulating B cells strongly predict vaccine response.
Authors: P F M Teunis; J C H van Eijkeren; W F de Graaf; A Bonačić Marinović; M E E Kretzschmar Journal: Epidemics Date: 2016-04-28 Impact factor: 4.396
Authors: Lee M Greenberger; Larry A Saltzman; Jonathon W Senefeld; Patrick W Johnson; Louis J DeGennaro; Gwen L Nichols Journal: Cancer Cell Date: 2021-07-22 Impact factor: 31.743
Authors: Paola Ghione; Juan J Gu; Kristopher Attwood; Pallawi Torka; Shipra Goel; Suchitra Sundaram; Cory Mavis; Michael Johnson; Roshneke Thomas; Kenneth Michael McWhite; Andrea Darrall; Joseph DeMarco; Jessica Kostrewa; Alice Mohr; Leah Rivas; Mirdza Neiders; Lakshmanan Suresh; Brahm H Segal; Elizabeth A Griffiths; Vincent Ramsperger; Long Shen; Francisco J Hernandez-Ilizaliturri Journal: Blood Date: 2021-06-29 Impact factor: 22.113
Authors: Michelle L Holshue; Chas DeBolt; Scott Lindquist; Kathy H Lofy; John Wiesman; Hollianne Bruce; Christopher Spitters; Keith Ericson; Sara Wilkerson; Ahmet Tural; George Diaz; Amanda Cohn; LeAnne Fox; Anita Patel; Susan I Gerber; Lindsay Kim; Suxiang Tong; Xiaoyan Lu; Steve Lindstrom; Mark A Pallansch; William C Weldon; Holly M Biggs; Timothy M Uyeki; Satish K Pillai Journal: N Engl J Med Date: 2020-01-31 Impact factor: 91.245
Authors: William A Wood; Donna S Neuberg; J Colton Thompson; Martin S Tallman; Mikkael A Sekeres; Laurie H Sehn; Kenneth C Anderson; Aaron D Goldberg; Nathan A Pennell; Charlotte M Niemeyer; Emily Tucker; Kathleen Hewitt; Robert M Plovnick; Lisa K Hicks Journal: Blood Adv Date: 2020-12-08
Authors: Evan J Anderson; Nadine G Rouphael; Alicia T Widge; Lisa A Jackson; Paul C Roberts; Mamodikoe Makhene; James D Chappell; Mark R Denison; Laura J Stevens; Andrea J Pruijssers; Adrian B McDermott; Britta Flach; Bob C Lin; Nicole A Doria-Rose; Sijy O'Dell; Stephen D Schmidt; Kizzmekia S Corbett; Phillip A Swanson; Marcelino Padilla; Kathy M Neuzil; Hamilton Bennett; Brett Leav; Mat Makowski; Jim Albert; Kaitlyn Cross; Venkata Viswanadh Edara; Katharine Floyd; Mehul S Suthar; David R Martinez; Ralph Baric; Wendy Buchanan; Catherine J Luke; Varun K Phadke; Christina A Rostad; Julie E Ledgerwood; Barney S Graham; John H Beigel Journal: N Engl J Med Date: 2020-09-29 Impact factor: 91.245
Authors: Sean H Lim; Nicola Campbell; Marina Johnson; Debora Joseph-Pietras; Graham P Collins; Ann O'Callaghan; Christopher P Fox; Matthew Ahearne; Peter W M Johnson; David Goldblatt; Andrew J Davies Journal: Lancet Haematol Date: 2021-07-02 Impact factor: 18.959
Authors: Kristen W Cohen; Susanne L Linderman; Zoe Moodie; Julie Czartoski; Lilin Lai; Grace Mantus; Carson Norwood; Lindsay E Nyhoff; Venkata Viswanadh Edara; Katharine Floyd; Stephen C De Rosa; Hasan Ahmed; Rachael Whaley; Shivan N Patel; Brittany Prigmore; Maria P Lemos; Carl W Davis; Sarah Furth; James B O'Keefe; Mohini P Gharpure; Sivaram Gunisetty; Kathy Stephens; Rustom Antia; Veronika I Zarnitsyna; David S Stephens; Srilatha Edupuganti; Nadine Rouphael; Evan J Anderson; Aneesh K Mehta; Jens Wrammert; Mehul S Suthar; Rafi Ahmed; M Juliana McElrath Journal: Cell Rep Med Date: 2021-07-03